2. Search Result
Search Result
Pathways Recommended: Neuronal Signaling
Results for "

neuronal hyperexcitability

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147423
    Zandatrigine
    1 Publications Verification

    NBI-921352; XEN901

    		 Sodium Channel Neurological Disease
    Zandatrigine (NBI-921352; XEN901) is a selective, orally active, voltage-gated sodium channel NaV1.6/SCN8A inhibitor that can penetrate the blood-brain barrier. Zandatrigine inhibits sodium influx by non-covalently binding to the VSD4 structure of NaV1.6, blocking the persistent and resuscitative currents under pathological conditions. Zandatrigine can reduce neuronal hyperexcitability and reduce epileptic seizures. Zandatrigine is 134-756-fold selective for other isoforms such as NaV1.1 and NaV1.2, and has minimal effect on NaV1.1 expressed by inhibitory interneurons. Zandatrigine can be used to study NaV1.6-mediated neuroexcitability diseases such as SCN8A-related developmental epileptic encephalopathy (SCN8A-DEE) and adult focal epilepsy .
    Zandatrigine
  • HY-A0042
    Rufinamide

    CGP 33101; E 2080; RUF 331

    		 Sodium Channel Neurological Disease
    Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
    Rufinamide
  • HY-15416
    NS309

    		Potassium Channel Cardiovascular Disease Neurological Disease
    NS309 is a potent and selective activator of the Ca 2+-activated SK/IK potassium channels, but displays no activity at BK channels .
    NS309
  • HY-110162
    QO 58

    		Potassium Channel Neurological Disease
    QO 58 is a potent modulator of K(v)7 channels. QO-58 increases the current amplitudes, shifts the voltage-dependent activation curve in a more negative direction and slows the deactivation of K(v)7.2/K(v)7.3 currents. QO-58 has the potential for the research of diseases associated with neuronal hyperexcitability .
    QO 58
  • HY-123264
    RL648_81

    		Potassium Channel Neurological Disease
    RL648_81 is a specific KQT-like subfamily 2/3 (KCNQ2/3) activator with an EC50 of 190 nM. RL648_81 robustly shifts the V1/2 of KCNQ2/3 channels towards hyperpolarized potentials.RL648_81 does not shift the V1/2 of either KCNQ4 or KCNQ5.RL648_81 has?the?potential?for?neurologic disorders associated with neuronal hyperexcitability research .
    RL648_81
  • HY-174146
    5-HT1A agonist 1

    		5-HT Receptor Neurological Disease
    5-HT1A agonist 1 (Compound Ex.37) is a highly selective 5-HT1a receptor agonist (EC50=0.18 nM). 5-HT1A agonist 1 mimicks serotonin binding to the receptor, promotes postsynaptic membrane hyperpolarization, inhibits neuronal hyperexcitability, and reduces the release of anxiety-related neurotransmitters. 5-HT1A agonist 1 is promising for research of neuropsychiatric diseases .
    5-HT1A agonist 1
  • HY-A0042R
    Rufinamide (Standard)

    CGP 33101 (Standard); E 2080 (Standard); RUF 331 (Standard)

    		 Sodium Channel Reference Standards Neurological Disease
    Rufinamide (Standard) is the analytical standard of Rufinamide (HY-A0042). This product is intended for research and analytical applications. Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
    Rufinamide (Standard)
  • HY-A0042S
    Rufinamide-d2

    CGP 33101-d2; E 2080-d2; RUF 331-d2

    		 Isotope-Labeled Compounds Sodium Channel Neurological Disease
    Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide (HY-A0042). Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
    Rufinamide-d2
  • HY-A0042S1
    Rufinamide-15N,d2

    CGP 33101-15N,d2; E 2080-15N,d2; RUF 331-15N,d2

    		 Isotope-Labeled Compounds Sodium Channel Neurological Disease
    Rufinamide- 15N,d2 (CGP 33101- 15N,d2) is the deuterium and 15N labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
    Rufinamide-15N,d2
  • HY-A0042S2
    Rufinamide-15N,d2-1

    CGP 33101-15N,d2-1; E 2080-15N,d2-1; RUF 331-15N,d2-1

    		 Isotope-Labeled Compounds Sodium Channel Neurological Disease
    Rufinamide- 15N,d2-1 (CGP 33101- 15N,d2-1) is 15N- and deuterium-labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na + current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome .
    Rufinamide-15N,d2-1
  • HY-182459
    Org 34167 (freebase)

    		HCN Channel Neurological Disease
    Org 34167 freebase is a blood-brain barrier permeable HCN channel modulator. Org 34167 freebase possesses high Caco-2 cell permeability. Org 34167 freebase modulates HCN channel function to alter activation properties and suppress neuronal hyperexcitability. Org 34167 freebase induces tremors in mice at specific doses. Org 34167 freebase acts as a research tool for studies on developmental and epileptic encephalopathies as well as depression .
    Org 34167 (freebase)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: